만성 정맥 폐색 치료 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Chronic Venous Occlusions Treatment Market was valued at USD 6.6 billion in 2023 and is projected to grow at a CAGR of 5.0% from 2024-2032. The market is driven by increased awareness and technological advancements. The rising prevalence of chronic venous diseases like chronic venous insufficiency (CVI) and deep vein thrombosis (DVT) is boosting demand for effective treatments. Minimally invasive procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), are gaining popularity due to faster recovery times and lower risks. Advanced imaging technologies like duplex ultrasound have improved diagnostic accuracy and treatment planning. Personalized medicine is driving the development of tailored therapies, enhancing treatment efficacy and patient care.

The overall chronic venous occlusions treatment industry is classified based on the product, application, end use , and region.

The market is segmented into devices and drugs, with the drugs segment projected to surpass USD 5.1 billion by 2032. Various drugs, including analgesics, antibiotics, and anticoagulants, are used in diagnosis and therapy. Antibiotics are preferred for treating ulcers and skin infections from CVI. The rise of direct oral anticoagulants (DOACs) offers improved safety and convenience, driving their adoption. Government and healthcare policies supporting drug reimbursement and access are further bolstering market growth. Increased R&D investments are accelerating the introduction of new drugs and addressing unmet medical needs.

The market is also segmented by application, including deep vein thrombosis, edema, venous stasis ulcers, varicose veins, and other applications. The edema segment is expected to exceed USD 2.9 billion by 2032. The prevalence of conditions like heart failure, kidney disease, and venous insufficiency, which lead to edema, is increasing demand for effective treatments. Advances in pharmacological therapies, such as diuretics and anti-inflammatory drugs, are improving management and treatment outcomes. The aging population and innovative drug formulations are driving segment expansion.

In 2023, North America accounted for USD 2.7 billion in revenue from the chronic venous occlusion's treatment market, with robust growth projected. The high prevalence of chronic venous diseases, advanced healthcare infrastructure, and minimally invasive procedures are key drivers. Government support through favorable reimbursement policies and health insurance coverage is broadening access to advanced treatments. Ongoing R&D investments are fostering innovation and the introduction of new therapies, solidifying North America's position as a market leader.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of varicose veins coupled with rising awareness regarding its treatment
    • 3.2.1.2 Growing preference for minimally invasive procedures
    • 3.2.1.3 Rise in number of orthopedic procedures
    • 3.2.1.4 Technological advancements pertaining to chronic venous insufficiency treatment therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks associated with different treatment modes
    • 3.2.2.2 Strict regulatory guidelines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Treatment landscape
• 3.7 Future market trends
• 3.8 Technological landscape
• 3.9 Epidemiology scenario
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Compression devices
  • 5.2.2 Endovenous ablation
    • 5.2.2.1 Laser ablation
    • 5.2.2.2 Radiofrequency ablation
  • 5.2.3 Sclerotherapy
  • 5.2.4 Vein stripper
  • 5.2.5 Other devices
• 5.3 Drugs
  • 5.3.1 Analgesics
  • 5.3.2 Antibiotics
  • 5.3.3 Anticoagulants
  • 5.3.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Varicose veins
• 6.3 Venous stasis ulcers
• 6.4 Edema
• 6.5 Deep vein thrombosis
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 3M Company
• 9.2 Bayer AG
• 9.3 Boston Scientific Corporation
• 9.4 Candela
• 9.5 ConvaTec Inc.
• 9.6 Fotona
• 9.7 Julius Zorn GmbH
• 9.8 Leucadia Pharmaceuticals (Hikma)
• 9.9 Medi GmbH and Co. KG
• 9.10 Medtronic plc
• 9.11 Merz Pharma
• 9.12 Pfizer Inc.
• 9.13 Sanofi
• 9.14 Sciton, Inc
• 9.15 Tactile Medical
• 9.16 Venclose, Inc. (Becton Dickinson and Company)
• 9.17 Viatris Inc.